Results 71 to 80 of about 9,306,982 (363)

Genetic Diversity and Expanded Phenotypes in Dystonia: Insights From Large‐Scale Exome Sequencing

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Dystonia is one of the most prevalent movement disorders, characterized by significant clinical and etiological heterogeneity. Despite considerable heritability (~25%), the etiology in most patients remains elusive. Moreover, understanding correlations between clinical manifestations and genetic variants has become increasingly ...
Mirja Thomsen   +47 more
wiley   +1 more source

MOESM1 of Brain mediators of systemic oxidative stress on perceptual impairments in Parkinsonâ s disease

open access: yes, 2015
Additional file 1. Detail T1-weighted structural MRI image processing procedures.
Wei-Che Lin   +12 more
openaire   +1 more source

The MSA Atrophy Index (MSA‐AI): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Reliable biomarkers are essential for tracking disease progression and advancing treatments for multiple system atrophy (MSA). In this study, we propose the MSA Atrophy Index (MSA‐AI), a novel composite volumetric measure to distinguish MSA from related disorders and monitor disease progression. Methods Seventeen participants with an
Paula Trujillo   +11 more
wiley   +1 more source

Online cognitive monitoring technology for people with Parkinson’s disease and REM sleep behavioural disorder

open access: yesnpj Digital Medicine
Automated online cognitive assessments are set to revolutionise clinical research and healthcare. However, their applicability for Parkinson’s Disease (PD) and REM Sleep Behavioural Disorder (RBD), a strong PD precursor, is underexplored.
Maria Bălăeţ   +13 more
doaj   +1 more source

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

open access: yesTranslational Neurodegeneration, 2020
Background The efficacy and safety of opicapone, a once-daily catechol-O-methyltransferase inhibitor, have been established in two large randomized, placebo-controlled, multinational pivotal trials.
Heinz Reichmann   +5 more
doaj   +1 more source

MOESM1 of A randomized controlled efficacy study of the Medido medication dispenser in Parkinsonâ s disease

open access: yes, 2019
Additional file 1. Table with secondary outcomes of PDQ-39.
K. Hannink   +8 more
openaire   +1 more source

Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease

open access: yesNature Genetics, 2009
We performed a genome-wide association study (GWAS) in 1,713 individuals of European ancestry with Parkinson's disease (PD) and 3,978 controls. After replication in 3,361 cases and 4,573 controls, we observed two strong association signals, one in the ...
J. Simón-Sánchez   +46 more
semanticscholar   +1 more source

Paroxysmal Dyskinesias Secondary to HHV‐6A Encephalitis: The First Case Report and Literature Review

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Paroxysmal dyskinesias encompasses a spectrum of conditions marked by intermittent involuntary movements, with paroxysmal kinesigenic dyskinesias being the most common phenotype. Central nervous system infection is a rare cause of paroxysmal dyskinesias.
Zhuoran Wang   +5 more
wiley   +1 more source

Reply to Comment on Re-Visiting Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 2019, 11, 491

open access: yesToxins, 2020
We appreciate the commentary on our article by Foster and Beard, both employees of Ipsen [...]
Steven Bellows, Joseph Jankovic
doaj   +1 more source

Additional file 2: of Meta-analysis of risk factors for Parkinsonâ s disease dementia

open access: yes, 2016
Details of the study results. This file provided detailed results of meta-analysis of each risk factor. (DOCX 159 kb)
Yaqian Xu, Yang, Jing, Huifang Shang
openaire   +1 more source

Home - About - Disclaimer - Privacy